Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial
- PMID: 17069542
- DOI: 10.1089/cap.2006.16.525
Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial
Abstract
A Phase II, 4-week randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the safety and efficacy of the Ampakine compound CX516 as a potential treatment for the underlying disorder in fragile X syndrome (FXS). After baseline screening, subjects with FXS (n = 49) underwent a 1-week placebo lead-in and then were randomized to study drug or placebo for a 4-week period. Cognitive and behavioral outcome measures were administered prior to treatment, at the end of treatment, and 2 weeks posttreatment. There were minimal side effects, no significant changes in safety parameters, and no serious adverse events. There was a 12.5% frequency of allergic rash in the CX516 group and 1 subject developed a substantial rash. There was also no significant improvement in memory, the primary outcome measure, or in secondary measures of language, attention/executive function, behavior, and overall functioning in CX516-treated subjects compared to placebo. This study did demonstrate that many outcome measures were reproducible in this test-retest setting for the FXS population, yet some were too difficult or variable. Adult subjects with FXS were able to complete an intensive clinical trial, and some valid outcome measures were identified for future FXS trial design. Problems with potency of CX516 in other studies have suggested dosing may have been inadequate for therapeutic effect and thus it remains unclear whether modulation of AMPA-mediated neurotransmission is a viable therapeutic strategy for the treatment of FXS.
Similar articles
-
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.Neuropsychopharmacology. 2008 Feb;33(3):465-72. doi: 10.1038/sj.npp.1301444. Epub 2007 May 9. Neuropsychopharmacology. 2008. PMID: 17487227 Free PMC article. Clinical Trial.
-
Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report.J Mol Neurosci. 2002 Aug-Oct;19(1-2):197-200. doi: 10.1007/s12031-002-0032-4. J Mol Neurosci. 2002. PMID: 12212780 Clinical Trial.
-
Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome.J Dev Behav Pediatr. 2008 Aug;29(4):293-302. doi: 10.1097/DBP.0b013e31817dc447. J Dev Behav Pediatr. 2008. PMID: 18698192 Clinical Trial.
-
Systematic review of pharmacological treatments in fragile X syndrome.BMC Neurol. 2009 Oct 13;9:53. doi: 10.1186/1471-2377-9-53. BMC Neurol. 2009. PMID: 19822023 Free PMC article. Review.
-
Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.Pediatr Neurol. 2014 Apr;50(4):297-302. doi: 10.1016/j.pediatrneurol.2013.12.001. Epub 2013 Dec 4. Pediatr Neurol. 2014. PMID: 24518745 Review.
Cited by
-
Reliability of resting-state electrophysiology in fragile X syndrome.Biomark Neuropsychiatry. 2023 Dec;9:100070. doi: 10.1016/j.bionps.2023.100070. Epub 2023 Jul 19. Biomark Neuropsychiatry. 2023. PMID: 38817342 Free PMC article.
-
The feasibility and utility of hair follicle sampling to measure FMRP and FMR1 mRNA in children with or without fragile X syndrome: a pilot study.J Neurodev Disord. 2022 Dec 9;14(1):57. doi: 10.1186/s11689-022-09465-7. J Neurodev Disord. 2022. PMID: 36494616 Free PMC article.
-
Long-term follow-up of telehealth-enabled behavioral treatment for challenging behaviors in boys with fragile X syndrome.J Neurodev Disord. 2022 Sep 30;14(1):53. doi: 10.1186/s11689-022-09463-9. J Neurodev Disord. 2022. PMID: 36180840 Free PMC article.
-
Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road.Drug Discov Today. 2021 Dec;26(12):2816-2838. doi: 10.1016/j.drudis.2021.07.027. Epub 2021 Aug 3. Drug Discov Today. 2021. PMID: 34358693 Free PMC article. Review.
-
Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement.Sci Rep. 2021 Jul 15;11(1):14532. doi: 10.1038/s41598-021-93888-0. Sci Rep. 2021. PMID: 34267258 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical